Nyxoah S.A. (NYXH)

Market Cap	241.21M
Revenue (ttm)	5.57M
Net Income (ttm)	-46.97M
Shares Out	34.36M
EPS (ttm)	-1.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,704
Open	7.05
Previous Close	7.10
Day's Range	6.76 - 7.28
52-Week Range	4.00 - 20.00
Beta	0.53
Analysts	Strong Buy
Price Target	16.67 (+137.46%)
Earnings Date	Aug 6, 2024

About NYXH

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jul 2, 2021
• Employees: 146
• Stock Exchange: NASDAQ
• Ticker Symbol: NYXH

Financial Performance

In 2023, Nyxoah's revenue was 4.35 million, an increase of 40.99% compared to the previous year's 3.08 million. Losses were -43.21 million, 38.4% more than in 2022.

Financial numbers in EUR

Analyst Forecast

According to 6 analysts, the average rating for NYXH stock is "Strong Buy." The 12-month stock price forecast is $16.67, which is an increase of 137.46% from the latest price.

Price Target

$16.67

(137.46% upside)

Analyst Consensus: Strong Buy